Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 39
Mycoses ; 66(1):45265.0, 2023.
Article in English | Scopus | ID: covidwho-2240067


Background: Isolated tracheobronchial mucormycosis (ITBM) is an uncommonly reported entity. Herein, we report a case of ITBM following coronavirus disease 2019 (COVID-19) and perform a systematic review of the literature. Case description and systematic review: A 45-year-old gentleman with poorly controlled diabetes mellitus presented with cough, streaky haemoptysis, and hoarseness of voice 2 weeks after mild COVID-19 illness. Computed tomography and flexible bronchoscopy suggested the presence of a tracheal mass, which was spontaneously expectorated. Histopathological examination of the mass confirmed invasive ITBM. The patient had complete clinical and radiological resolution with glycaemic control, posaconazole, and inhaled amphotericin B (8 weeks). Our systematic review of the literature identified 25 additional cases of isolated airway invasive mucormycosis. The median age of the 26 subjects (58.3% men) was 46 years. Diabetes mellitus (79.2%) was the most common risk factor. Uncommon conditions such as anastomosis site mucormycosis (in two lung transplant recipients), post-viral illness (post-COVID-19 [n = 3], and influenza [n = 1]), and post-intubation mucormycosis (n = 1) were noted in a few. Three patients died before treatment initiation. Systemic antifungals were used in most patients (commonly amphotericin B). Inhalation (5/26;19.2%) or bronchoscopic instillation (1/26;3.8%) of amphotericin B and surgery (6/26;23.1%) were performed in some patients. The case-fatality rate was 50%, primarily attributed to massive haemoptysis. Conclusion: Isolated tracheobronchial mucormycosis is a rare disease. Bronchoscopy helps in early diagnosis. Management with antifungals and control of risk factors is required since surgery may not be feasible. © 2022 Wiley-VCH GmbH.

Pan African Medical Journal ; 37(Supplement 1) (no pagination), 2020.
Article in English | EMBASE | ID: covidwho-2230788


The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 has rapidly spread globally with significant negative impact on health. There is an urgent need for a drug or vaccine certified for treating and preventing COVID-19 respectively. Tocilizumab, an interleukin-6 monoclonal receptor antibody, has been used in some centers for mitigating the severe inflammatory response seen in patients with severe COVID-19 with encouraging results. To the best of our knowledge, reports detailing the outcomes of patients with severe COVID-19 undergoing treatment with tocilizumab are sparse in sub-Saharan Africa. We describe the clinical and laboratory profile, chest Computed Tomography (CT) scan findings and clinical outcome in a Ghanaian patient with severe COVID-19 pneumonia treated with tocilizumab. A 54-year old hypertensive male presented with fever, productive cough, pleuritic chest pain and breathlessness. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction analysis done on a nasopharyngeal swab sample. His respiratory symptoms worsened while on admission despite receiving standard of care. His C-reactive protein (CRP) was elevated to 80.59mg/L and chest CT scan findings were indicative of severe COVID-19 pneumonia. He was treated with a single 400mg dose of intravenous tocilizumab with a positive clinical outcome, rapid decline in CRP and improvement in chest CT findings. Our experience shows that tocilizumab shows great promise as drug therapy for COVID-19 pneumonia. Copyright © 2020, African Field Epidemiology Network. All rights reserved.

ARS Medica Tomitana ; 27(1):31-35, 2021.
Article in English | EMBASE | ID: covidwho-2065353
Chest ; 162(4):A2443, 2022.
Article in English | EMBASE | ID: covidwho-2060944
Chest ; 162(4):A2226, 2022.
Article in English | EMBASE | ID: covidwho-2060914
Chest ; 162(4):A1858, 2022.
Article in English | EMBASE | ID: covidwho-2060875
Chest ; 162(4):A1773, 2022.
Article in English | EMBASE | ID: covidwho-2060858
Chest ; 162(4):A1720-A1721, 2022.
Article in English | EMBASE | ID: covidwho-2060854
Chest ; 162(4):A1265, 2022.
Article in English | EMBASE | ID: covidwho-2060791
Chest ; 162(4):A1000, 2022.
Article in English | EMBASE | ID: covidwho-2060747
Chest ; 162(4):A562-A563, 2022.
Article in English | EMBASE | ID: covidwho-2060632
Chest ; 162(4):A560, 2022.
Article in English | EMBASE | ID: covidwho-2060631
Chest ; 162(4):A462, 2022.
Article in English | EMBASE | ID: covidwho-2060600
Chest ; 162(4):A414, 2022.
Article in English | EMBASE | ID: covidwho-2060590
Chest ; 162(4):A371, 2022.
Article in English | EMBASE | ID: covidwho-2060577
Indian Journal of Critical Care Medicine ; 26:S51-S52, 2022.
Article in English | EMBASE | ID: covidwho-2006347
Journal of General Internal Medicine ; 37:S473, 2022.
Article in English | EMBASE | ID: covidwho-1995839
Journal of General Internal Medicine ; 37:S457, 2022.
Article in English | EMBASE | ID: covidwho-1995812
Journal of General Internal Medicine ; 37:S521, 2022.
Article in English | EMBASE | ID: covidwho-1995801